7,556.92

+15.52

+0.21%

51,729.68

-254.30

-0.49%

25,285.33

+120.97

+0.48%

2,805.88

-5.97

-0.21%

4.9190

+0.0250

+0.51%

20.98

-0.17

-0.80%

3,954.70

-14.90

-0.38%

77,214.21

-533.69

-0.69%

Crude Oil Dec 26

96.07

-0.39

-0.40%

US Private Equity

10,836.30

-14.33

-0.13%

Stockholm - Free Realtime Quote SEK

BioInvent International AB (publ) (BINV.ST)

3.7750 -0.5250 (-12.21%)

As of 2:02:37 PM GMT+1. Market Open.

Loading Chart for BINV.ST

Chart Range Bar

Interval:

In partnership with ChartIQ

Invitation to Presentation of BioInvent's Interim Report January - September 2026

Invitation to Presentation of BioInvent's Interim Report January - September 2026

BioInvent's BI-1808 and KEYTRUDA(R) Induce Durable Responses in Heavily Pretreated Platinum-Resistant Ovarian Cancer

BioInvent's BI-1808 and KEYTRUDA(R) Induce Durable Responses in Heavily Pretreated Platinum-Resistant Ovarian Cancer

BioInvent To Present BI-1808 Data in Platinum-Resistant Recurrent Ovarian Cancer at ESMO 2026

BioInvent To Present BI-1808 Data in Platinum-Resistant Recurrent Ovarian Cancer at ESMO 2026

BioInvent Announces Publication of First-in-Human BI-1808 Data in Clinical Cancer Research

BioInvent Announces Publication of First-in-Human BI-1808 Data in Clinical Cancer Research

BioInvent International AB Announces that its CFO will Retire in 2027

BioInvent International AB Announces that its CFO will Retire in 2027

BioInvent Announces Publication of Preclinical Manuscript on BI-1808 and BI-1910 in Cancer Research

BioInvent Announces Publication of Preclinical Manuscript on BI-1808 and BI-1910 in Cancer Research

BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Ovarian Cancer

BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Ovarian Cancer

BioInvent Publication in JECCR: Tailored FcγR Blockade with BI-1206 and BI-1607 Enhances Cancer Antibody Therapies and Overcomes Resistance in Preclinical Models

BioInvent Publication in JECCR: Tailored FcγR Blockade with BI-1206 and BI-1607 Enhances Cancer Antibody Therapies and Overcomes Resistance in Preclinical Models

BioInvent's BI-1808 Abstract from Modest to Meaningful in Platinum-Resistant Ovarian Cancer Accepted for Poster Presentation at ESMO 2026

BioInvent's BI-1808 Abstract from Modest to Meaningful in Platinum-Resistant Ovarian Cancer Accepted for Poster Presentation at ESMO 2026

BioInvent to Host a KOL Event in Stockholm on June 11, 2026, to Discuss Updated BI-1206 & BI-1808 Data in Hematology

BioInvent to Host a KOL Event in Stockholm on June 11, 2026, to Discuss Updated BI-1206 & BI-1808 Data in Hematology

Resolutions at BioInvent's Annual General Meeting 2026

Resolutions at BioInvent's Annual General Meeting 2026

Mobilize your Website

View Site in Mobile | Classic

Share by: